Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (14.6), the stock would be worth ₹90.29 (34% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.1 | ₹137.02 |
0%
|
| 3-Year Average | 14.6 | ₹90.29 |
-34%
|
| 5-Year Average | 14.6 | ₹90.29 |
-34%
|
| Industry Average | 28 | ₹173.16 |
+26%
|
| Country Average | 23.4 | ₹145.12 |
+6%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
|
3.2B INR | 22.1 | 33.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.1 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.6 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 14.7 |
| Median | 23.4 |
| 70th Percentile | 39.6 |
| Max | 28 676 |
Other Multiples
Bafna Pharmaceuticals Ltd
Glance View
Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is manufacturing over 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. The firm caters to both domestic and international markets. The firm has two manufacturing facilities in Chennai. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The firm supplies its finished products to countries including Sri Lanka, Ghana, Ukraine, and Laos. The firm's subsidary include Bafna Lifestyles Remedies Limited.
